Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sildenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 0.77 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.77 |
| ▸ | PDE1A | P54750 | 3/20 | 0.77 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.77 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.77 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.77 |
| ▸ | PDE2A | O00408 | 1/20 | 0.77 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.77 |
| ▸ | PDE6D | O43924 | 1/20 | 0.77 |
| ▸ | PDE8A | O60658 | 1/20 | 0.77 |
| ▸ | PDE9A | O76083 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | HTR1A | P08908 | 1/20 | 0.77 |
| ▸ | PDE6A | P16499 | 1/20 | 0.77 |
| ▸ | PDE6G | P18545 | 1/20 | 0.77 |
| ▸ | PDE4A | P27815 | 1/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18912665 | 0.94 | PDE5A (0.68) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL19254528 | 0.94 | PDE5A (0.78) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL19518061 | 0.93 | PDE5A (0.77) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL2033330 | 0.92 | PDE5A (0.66) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL18912667 | 0.92 | PDE5A (0.65) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL30199978 | 0.92 | PDE5A (0.74) | PDE5APDE3BPDE3APDE1APDE1B | |
| Lodenafil SCHEMBL18416781 | 0.91 | PDE5A (0.78) | PDE5APDE3BPDE3APDE1APDE1B | |
| Sildenafil SCHEMBL1652668 | 0.91 | PDE5A (0.81) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL12341666 | 0.89 | PDE5A (0.65) | PDE5APDE3BPDE3APDE1APDE1B | |
| Lodenafil Carbonate SCHEMBL18074278 | 0.89 | PDE5A (0.66) | PDE5APDE3BPDE3APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1570 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12038436-B2 | Diagnosis of autoimmune disease | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-07-16 | — | — | US | claimed |
| US-20230310478-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION AND CANCER | ZHAO, Youyang | 2023-10-05 | — | — | US | claimed |
| US-20230045855-A1 | DIAGNOSIS OF AUTOIMMUNE DISEASE | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2023-02-16 | — | — | US | claimed |
| WO-2022051495-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION AND CANCER | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (US) | 2022-03-10 | — | — | WO | claimed |
| US-20190094219-A1 | DIAGNOSIS OF AUTOIMMUNE DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-03-28 | — | — | US | claimed |
| US-20160108406-A1 | METHOD OF REGULATING CFTR EXPRESSION AND PROCESSING | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-04-21 | — | — | US | claimed |
| US-8106061-B2 | Use of phosphodiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2012-01-31 | — | — | US | claimed |
| EP-1087953-B1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX SA (FR) | 2004-11-17 | — | — | EP | claimed |
| US-12624343-B2 | Extracellular vesicles (EVs) derived from mesenchymal stromal cells and method for obtaining said EVs | EXO BIOLOGICS SA (BE) | 2026-05-12 | — | — | US | disclosed |
| US-12622971-B2 | Linear polysaccharide based film products | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260092078-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-3668319-B1 | PURIFIED MESENCHYMAL STEM CELL EXOSOMES AND USES THEREOF | CHILDRENS MEDICAL CENTER (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-6645965-B1 | Sildenafil, hydralazine, minoxidil, or zaprinast; cardiovascular disorders | NICOX S.A. (FR) | 2003-11-11 | — | — | US | disclosed |
| EP-1357928-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | New River Pharmaceuticals Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003079972-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PARMACEUTICALS INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003020200-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-1999059584-A1 | COMBINATION OF PHENTOLAMINE AND CYCLIC GMP PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | SCHERING CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | HTR6, HTR3C, OPRD1 | PDE5A 1447/4885PDE3B 1433/4885PDE3A 2051/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | PDE5A 4784/4885PDE3B 4335/4885PDE3A 4647/4885 |
| US-12624343-B2 | Extracellular vesicles (EVs) derived from mesenchymal stromal cells and method for obtaining said EVs | CD63, TFRC, EXOSC9 | PDE5A 4589/4885PDE3B 4762/4885PDE3A 4785/4885 |
| US-20260092078-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, ADRM1, MDM2 | PDE5A 4434/4885PDE3B 4522/4885PDE3A 4454/4885 |
| US-12622971-B2 | Linear polysaccharide based film products | SORD, SMCHD1, PLEC | PDE5A 448/4885PDE3B 758/4885PDE3A 354/4885 |
| US-20230310478-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION AND CANCER | TOP2A, TOP2B, TOP1 | PDE5A 557/4885PDE3B 853/4885PDE3A 587/4885 |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | HDGF, CTSA, IAPP | PDE5A 3033/4885PDE3B 2572/4885PDE3A 2749/4885 |
| US-20160108406-A1 | METHOD OF REGULATING CFTR EXPRESSION AND PROCESSING | CFTR, NEDD8, SCNN1B | PDE5A 4305/4885PDE3B 4680/4885PDE3A 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.